Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take a drubbing. But at OSE Immunotherapeutics, which aims to prevent cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results